JP2009536219A - ロドプシン拡散のインビボ送達による視覚応答の回復 - Google Patents
ロドプシン拡散のインビボ送達による視覚応答の回復 Download PDFInfo
- Publication number
- JP2009536219A JP2009536219A JP2009510101A JP2009510101A JP2009536219A JP 2009536219 A JP2009536219 A JP 2009536219A JP 2009510101 A JP2009510101 A JP 2009510101A JP 2009510101 A JP2009510101 A JP 2009510101A JP 2009536219 A JP2009536219 A JP 2009536219A
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- light
- retinal
- cells
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000007 visual effect Effects 0.000 title claims abstract description 80
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 title claims abstract description 20
- 108090000820 Rhodopsin Proteins 0.000 title claims abstract description 19
- 102000004330 Rhodopsin Human genes 0.000 title claims abstract 9
- 230000004044 response Effects 0.000 title claims description 73
- 238000001727 in vivo Methods 0.000 title description 14
- 238000011084 recovery Methods 0.000 title description 14
- 238000009792 diffusion process Methods 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract description 169
- 238000000034 method Methods 0.000 claims abstract description 117
- 210000001525 retina Anatomy 0.000 claims abstract description 98
- 210000001116 retinal neuron Anatomy 0.000 claims abstract description 80
- 239000013598 vector Substances 0.000 claims abstract description 67
- 230000004438 eyesight Effects 0.000 claims abstract description 51
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 29
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 24
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 24
- 206010034972 Photosensitivity reaction Diseases 0.000 claims abstract description 23
- 230000036211 photosensitivity Effects 0.000 claims abstract description 23
- 230000001105 regulatory effect Effects 0.000 claims abstract description 23
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims abstract description 20
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 108700026244 Open Reading Frames Proteins 0.000 claims abstract description 8
- 208000002780 macular degeneration Diseases 0.000 claims abstract description 6
- 230000002103 transcriptional effect Effects 0.000 claims abstract description 5
- 230000014509 gene expression Effects 0.000 claims description 86
- 230000002207 retinal effect Effects 0.000 claims description 50
- 210000002569 neuron Anatomy 0.000 claims description 37
- 210000003994 retinal ganglion cell Anatomy 0.000 claims description 37
- 108091006146 Channels Proteins 0.000 claims description 36
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 34
- 208000005400 Synovial Cyst Diseases 0.000 claims description 34
- 230000000638 stimulation Effects 0.000 claims description 33
- 201000004569 Blindness Diseases 0.000 claims description 29
- 238000012549 training Methods 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 239000012634 fragment Substances 0.000 claims description 25
- 239000013603 viral vector Substances 0.000 claims description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 23
- 102100038300 Metabotropic glutamate receptor 6 Human genes 0.000 claims description 19
- 108010038450 metabotropic glutamate receptor 6 Proteins 0.000 claims description 17
- 238000006467 substitution reaction Methods 0.000 claims description 16
- 210000000857 visual cortex Anatomy 0.000 claims description 16
- 239000007943 implant Substances 0.000 claims description 14
- 230000001939 inductive effect Effects 0.000 claims description 12
- 210000002508 rod bipolar cell Anatomy 0.000 claims description 11
- 206010034960 Photophobia Diseases 0.000 claims description 10
- 108010006025 bovine growth hormone Proteins 0.000 claims description 10
- 239000003623 enhancer Substances 0.000 claims description 10
- 208000013469 light sensitivity Diseases 0.000 claims description 10
- 230000008488 polyadenylation Effects 0.000 claims description 10
- 210000000411 amacrine cell Anatomy 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 claims description 8
- 210000003127 knee Anatomy 0.000 claims description 8
- 230000001054 cortical effect Effects 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 230000001124 posttranscriptional effect Effects 0.000 claims description 7
- 108010035848 Channelrhodopsins Proteins 0.000 claims description 6
- 241000283923 Marmota monax Species 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 108010083687 Ion Pumps Proteins 0.000 claims description 5
- 210000003986 cell retinal photoreceptor Anatomy 0.000 claims description 5
- 210000001328 optic nerve Anatomy 0.000 claims description 5
- 101100135809 Mus musculus Pcp2 gene Proteins 0.000 claims description 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 3
- 230000007613 environmental effect Effects 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 2
- 101001032837 Homo sapiens Metabotropic glutamate receptor 6 Proteins 0.000 claims 2
- 108091008695 photoreceptors Proteins 0.000 abstract description 51
- 239000007924 injection Substances 0.000 abstract description 24
- 238000002347 injection Methods 0.000 abstract description 24
- 230000007850 degeneration Effects 0.000 abstract description 18
- 108090000862 Ion Channels Proteins 0.000 abstract description 10
- 102000004310 Ion Channels Human genes 0.000 abstract description 10
- 238000010171 animal model Methods 0.000 abstract description 7
- 150000001768 cations Chemical class 0.000 abstract description 4
- 230000019771 cognition Effects 0.000 abstract description 3
- 239000005090 green fluorescent protein Substances 0.000 description 97
- 108090000623 proteins and genes Proteins 0.000 description 52
- 241000699670 Mus sp. Species 0.000 description 49
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 49
- 235000020945 retinal Nutrition 0.000 description 44
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 42
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 42
- 239000011604 retinal Substances 0.000 description 42
- 102000004169 proteins and genes Human genes 0.000 description 30
- 108700019146 Transgenes Proteins 0.000 description 28
- 230000006870 function Effects 0.000 description 28
- 102000004196 processed proteins & peptides Human genes 0.000 description 25
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 241000700605 Viruses Species 0.000 description 24
- 229920001184 polypeptide Polymers 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 20
- 238000013459 approach Methods 0.000 description 20
- 230000028161 membrane depolarization Effects 0.000 description 20
- 238000010304 firing Methods 0.000 description 19
- 208000035475 disorder Diseases 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 230000001404 mediated effect Effects 0.000 description 15
- 230000008447 perception Effects 0.000 description 15
- 108091026890 Coding region Proteins 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 14
- 210000004940 nucleus Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 210000000608 photoreceptor cell Anatomy 0.000 description 12
- 102100040756 Rhodopsin Human genes 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 10
- 201000007737 Retinal degeneration Diseases 0.000 description 10
- 230000000763 evoking effect Effects 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 230000037361 pathway Effects 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 230000004298 light response Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000004258 retinal degeneration Effects 0.000 description 9
- 210000002845 virion Anatomy 0.000 description 9
- 239000013607 AAV vector Substances 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 8
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 102000010175 Opsin Human genes 0.000 description 7
- 108050001704 Opsin Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000001415 gene therapy Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000033001 locomotion Effects 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 7
- 241000702421 Dependoparvovirus Species 0.000 description 6
- 101150027545 GRM6 gene Proteins 0.000 description 6
- 108700008625 Reporter Genes Proteins 0.000 description 6
- 208000017442 Retinal disease Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000004393 visual impairment Effects 0.000 description 6
- 102100025912 Melanopsin Human genes 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 210000003050 axon Anatomy 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108010005417 melanopsin Proteins 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000007634 remodeling Methods 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108010008445 Microbial Rhodopsins Proteins 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 230000027288 circadian rhythm Effects 0.000 description 4
- 230000002999 depolarising effect Effects 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 238000007699 photoisomerization reaction Methods 0.000 description 4
- 210000003569 retinal bipolar cell Anatomy 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 230000004382 visual function Effects 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- RPXVIAFEQBNEAX-UHFFFAOYSA-N 6-Cyano-7-nitroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+](=O)[O-])C(C#N)=C2 RPXVIAFEQBNEAX-UHFFFAOYSA-N 0.000 description 3
- 241000195597 Chlamydomonas reinhardtii Species 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 108010050754 Halorhodopsins Proteins 0.000 description 3
- 208000010415 Low Vision Diseases 0.000 description 3
- 208000022873 Ocular disease Diseases 0.000 description 3
- 206010038923 Retinopathy Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000036982 action potential Effects 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000002287 horizontal cell Anatomy 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 210000001153 interneuron Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000001743 on-bipolar cell Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000001747 pupil Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 210000002071 ventral thalamic nuclei Anatomy 0.000 description 3
- 230000016776 visual perception Effects 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 108010082845 Bacteriorhodopsins Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- 108700022034 Opsonin Proteins Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 238000001720 action spectrum Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002060 circadian Effects 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 239000012792 core layer Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000023077 detection of light stimulus Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 210000002592 gangliocyte Anatomy 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000004295 hippocampal neuron Anatomy 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000004297 night vision Effects 0.000 description 2
- 206010029864 nystagmus Diseases 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 108010079892 phosphoglycerol kinase Proteins 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 229910052724 xenon Inorganic materials 0.000 description 2
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
- 102000043281 11-cis-retinal-binding protein Human genes 0.000 description 1
- 108010038155 11-cis-retinal-binding protein Proteins 0.000 description 1
- NCYCYZXNIZJOKI-HPNHMNAASA-N 11Z-retinal Natural products CC(=C/C=O)C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-HPNHMNAASA-N 0.000 description 1
- 102100038794 17-beta-hydroxysteroid dehydrogenase type 6 Human genes 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 108010057856 Adenovirus E2 Proteins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010001949 Algal Proteins Proteins 0.000 description 1
- 241000702419 Ambidensovirus Species 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 206010005176 Blindness congenital Diseases 0.000 description 1
- 102100035344 Cadherin-related family member 1 Human genes 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000034573 Channels Human genes 0.000 description 1
- 241001510512 Chlamydia phage 2 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 101150009410 Chp2 gene Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 101100351286 Dictyostelium discoideum pdeE gene Proteins 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102100025623 Gap junction delta-2 protein Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
- 208000016605 Hereditary Eye disease Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000737767 Homo sapiens Cadherin-related family member 1 Proteins 0.000 description 1
- 101000710244 Homo sapiens Clathrin light chain A Proteins 0.000 description 1
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000032578 Inherited retinal disease Diseases 0.000 description 1
- 102000006391 Ion Pumps Human genes 0.000 description 1
- 201000002287 Keratoconus Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 101100451662 Mus musculus Prm1 gene Proteins 0.000 description 1
- 101000742949 Mus musculus Retinol dehydrogenase 5 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 101710131038 Opsin-2 Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288049 Perdix perdix Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 208000034461 Progressive cone dystrophy Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000002367 Retinal Perforations Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 208000032430 Retinal dystrophy Diseases 0.000 description 1
- 206010038897 Retinal tear Diseases 0.000 description 1
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 208000014769 Usher Syndromes Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 108700019030 adenovirus E4orf6 Proteins 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 206010001902 amaurosis Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000009391 cell specific gene expression Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 201000008615 cone dystrophy Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000006623 congenital stationary night blindness Diseases 0.000 description 1
- 108010015417 connexin 36 Proteins 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 206010011005 corneal dystrophy Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 238000003372 electrophysiological method Methods 0.000 description 1
- 230000013742 energy transducer activity Effects 0.000 description 1
- 230000034964 establishment of cell polarity Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 201000006321 fundus dystrophy Diseases 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 230000004303 low vision Effects 0.000 description 1
- 210000002189 macula lutea Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 230000034153 membrane organization Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 101150037969 pde-6 gene Proteins 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical group C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 230000029264 phototaxis Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 239000013608 rAAV vector Substances 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000000964 retinal cone photoreceptor cell Anatomy 0.000 description 1
- 150000003726 retinal derivatives Chemical class 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 230000004281 retinal morphology Effects 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 1
- 108010054126 retinoid isomerohydrolase Proteins 0.000 description 1
- 108010035291 retinol dehydrogenase Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000008454 sleep-wake cycle Effects 0.000 description 1
- ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000003863 superior colliculi Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000003945 visual behavior Effects 0.000 description 1
- 230000004400 visual pathway Effects 0.000 description 1
- 210000000239 visual pathway Anatomy 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79735706P | 2006-05-04 | 2006-05-04 | |
| PCT/US2007/068263 WO2007131180A2 (en) | 2006-05-04 | 2007-05-04 | Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013217117A Division JP2014040469A (ja) | 2006-05-04 | 2013-10-18 | ロドプシン拡散のインビボ送達による視覚応答の回復 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009536219A true JP2009536219A (ja) | 2009-10-08 |
| JP2009536219A5 JP2009536219A5 (https=) | 2011-06-16 |
Family
ID=38668588
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009510101A Pending JP2009536219A (ja) | 2006-05-04 | 2007-05-04 | ロドプシン拡散のインビボ送達による視覚応答の回復 |
| JP2013217117A Withdrawn JP2014040469A (ja) | 2006-05-04 | 2013-10-18 | ロドプシン拡散のインビボ送達による視覚応答の回復 |
| JP2016074113A Withdrawn JP2016121190A (ja) | 2006-05-04 | 2016-04-01 | ロドプシン拡散のインビボ送達による視覚応答の回復 |
| JP2018017334A Withdrawn JP2018076377A (ja) | 2006-05-04 | 2018-02-02 | ロドプシン拡散のインビボ送達による視覚応答の回復 |
| JP2020149721A Pending JP2020203924A (ja) | 2006-05-04 | 2020-09-07 | ロドプシン拡散のインビボ送達による視覚応答の回復 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013217117A Withdrawn JP2014040469A (ja) | 2006-05-04 | 2013-10-18 | ロドプシン拡散のインビボ送達による視覚応答の回復 |
| JP2016074113A Withdrawn JP2016121190A (ja) | 2006-05-04 | 2016-04-01 | ロドプシン拡散のインビボ送達による視覚応答の回復 |
| JP2018017334A Withdrawn JP2018076377A (ja) | 2006-05-04 | 2018-02-02 | ロドプシン拡散のインビボ送達による視覚応答の回復 |
| JP2020149721A Pending JP2020203924A (ja) | 2006-05-04 | 2020-09-07 | ロドプシン拡散のインビボ送達による視覚応答の回復 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US8470790B2 (https=) |
| EP (2) | EP2019588A4 (https=) |
| JP (5) | JP2009536219A (https=) |
| CN (1) | CN101484005A (https=) |
| AU (2) | AU2007247929A1 (https=) |
| CA (1) | CA2685900A1 (https=) |
| WO (1) | WO2007131180A2 (https=) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008201692A (ja) * | 2007-02-19 | 2008-09-04 | Tohoku Univ | 視覚機能の再生方法 |
| JP2013521017A (ja) * | 2010-02-26 | 2013-06-10 | コーネル ユニヴァーシティー | 人工網膜 |
| JP2013544494A (ja) * | 2010-09-08 | 2013-12-19 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | 変異チャネルロドプシン２ |
| JP2014524903A (ja) * | 2011-06-24 | 2014-09-25 | ハーク−シュトライト・メドテック・アクチェンゲゼルシャフト | 光感受性キメラｇｐｃｒタンパク質 |
| JP2016519063A (ja) * | 2013-03-14 | 2016-06-30 | ウェイン ステイト ユニバーシティー | 治療用化合物の眼への送達を増強する方法 |
| WO2018043707A1 (ja) * | 2016-09-02 | 2018-03-08 | 学校法人慶應義塾 | 視覚機能再生剤又は視覚機能低下予防剤 |
| JP2019505239A (ja) * | 2016-02-23 | 2019-02-28 | アイサーブ ゲーエムベーハーＥｙｅｓｅｒｖ Ｇｍｂｈ | 網膜変性疾患を治療するための遺伝子治療 |
| WO2020148913A1 (ja) * | 2019-01-18 | 2020-07-23 | 俊英 栗原 | 網膜疾患の予防および進行抑制、視覚認知行動機能の改善、および視覚機能強化 |
| WO2021182646A1 (ja) * | 2020-03-13 | 2021-09-16 | 国立大学法人名古屋工業大学 | 色認識のための光応答性タンパク質及びその利用 |
| US11771741B2 (en) | 2019-09-13 | 2023-10-03 | Restore Vision Inc. | Nucleic acid construct that encodes chimeric rhodopsin |
| US12606606B2 (en) | 2019-09-13 | 2026-04-21 | Restore Vision Inc. | Nucleic acid construct that encodes chimeric rhodopsin |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004009022A2 (en) | 2002-07-18 | 2004-01-29 | The General Hospital Corp. | Method for augmenting vision in persons suffering from photoreceptor cell degeneration |
| US9274099B2 (en) | 2005-07-22 | 2016-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Screening test drugs to identify their effects on cell membrane voltage-gated ion channel |
| US8926959B2 (en) | 2005-07-22 | 2015-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
| US10052497B2 (en) | 2005-07-22 | 2018-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
| US9238150B2 (en) | 2005-07-22 | 2016-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Optical tissue interface method and apparatus for stimulating cells |
| EP1919497B1 (en) | 2005-07-22 | 2020-02-12 | The Board of Trustees of the Leland Stanford Junior University | Light-activated cation channel and uses thereof |
| CN101484005A (zh) * | 2006-05-04 | 2009-07-15 | 韦恩州立大学 | 通过向体内递送视紫红质核酸恢复视觉响应 |
| WO2008086470A1 (en) | 2007-01-10 | 2008-07-17 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
| US8401609B2 (en) | 2007-02-14 | 2013-03-19 | The Board Of Trustees Of The Leland Stanford Junior University | System, method and applications involving identification of biological circuits such as neurological characteristics |
| WO2008106694A2 (en) | 2007-03-01 | 2008-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Systems, methods and compositions for optical stimulation of target cells |
| US10035027B2 (en) | 2007-10-31 | 2018-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Device and method for ultrasonic neuromodulation via stereotactic frame based technique |
| US10434327B2 (en) | 2007-10-31 | 2019-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Implantable optical stimulators |
| MX2010011467A (es) * | 2008-04-18 | 2011-02-15 | Novartis Forschungsstiftung | Novedosas herramientas y metodos terapeuticos para tratar la ceguera. |
| JP5801188B2 (ja) | 2008-04-23 | 2015-10-28 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 標的細胞を光刺激するためのシステム、方法、および組成物 |
| WO2010011404A2 (en) * | 2008-05-20 | 2010-01-28 | Eos Neuroscience, Inc. | Vectors for delivery of light-sensitive proteins and methods of use |
| MY152003A (en) | 2008-05-29 | 2014-08-15 | Univ Leland Stanford Junior | Cell line, system and method for optical control of secondary messengers |
| MY162929A (en) | 2008-06-17 | 2017-07-31 | Univ Leland Stanford Junior | Apparatus and methods for controlling cellular development |
| CA2728238C (en) | 2008-06-17 | 2019-03-12 | M. Bret Schneider | Methods, systems and devices for optical stimulation of target cells using an optical transmission element |
| CN102124109B (zh) * | 2008-06-30 | 2013-10-16 | Cho-A制药有限公司 | 猪α-S1-酪蛋白基因，其启动子及其用途 |
| US9101759B2 (en) | 2008-07-08 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Materials and approaches for optical stimulation of the peripheral nervous system |
| NZ602416A (en) | 2008-11-14 | 2014-08-29 | Univ Leland Stanford Junior | Optically-based stimulation of target cells and modifications thereto |
| EP2465931B1 (en) * | 2009-08-10 | 2014-12-24 | Tohoku University | Light-receiving channel rhodopsin having improved expression efficiency |
| EP2483394A1 (en) * | 2009-09-29 | 2012-08-08 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Functionalized organotypic systems |
| CN101693127B (zh) * | 2009-09-30 | 2014-10-08 | 深圳先进技术研究院 | 皮肤材料及其制备方法 |
| CN101812478B (zh) * | 2009-12-29 | 2012-07-25 | 中国人民解放军第四军医大学 | 用于提高汉坦病毒融合蛋白g1s0.7表达的腺病毒高表达载体 |
| US9180309B2 (en) | 2010-02-26 | 2015-11-10 | Cornell University | Retina prosthesis |
| EP2547762B1 (en) | 2010-03-17 | 2018-04-25 | The Board of Trustees of the Leland Stanford Junior University | Light-sensitive ion-passing molecules |
| US20130225664A1 (en) | 2010-04-05 | 2013-08-29 | Alan Horsager | Methods and compositions for decreasing chronic pain |
| WO2011140279A1 (en) * | 2010-05-04 | 2011-11-10 | Wayne State University | Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells |
| CA2838330C (en) | 2010-08-23 | 2021-01-26 | President And Fellows Of Harvard College | Optogenetic probes for measuring membrane potential |
| US9207237B2 (en) | 2010-08-23 | 2015-12-08 | President And Fellows Of Harvard College | Systems, methods, and workflows for optogenetics analysis |
| US9302103B1 (en) | 2010-09-10 | 2016-04-05 | Cornell University | Neurological prosthesis |
| WO2012051599A2 (en) | 2010-10-15 | 2012-04-19 | Eos Neuroscience, Inc. | Modulation neural pathways |
| WO2012061679A2 (en) | 2010-11-05 | 2012-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated chimeric opsins and methods of using the same |
| WO2012061688A1 (en) | 2010-11-05 | 2012-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of reward-related behaviors |
| CA2816968C (en) | 2010-11-05 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Optically-controlled cns dysfunction |
| US9522288B2 (en) | 2010-11-05 | 2016-12-20 | The Board Of Trustees Of The Leland Stanford Junior University | Upconversion of light for use in optogenetic methods |
| EP2635111B1 (en) | 2010-11-05 | 2018-05-23 | The Board of Trustees of the Leland Stanford Junior University | Stabilized step function opsin proteins and methods of using the same |
| CA2816972C (en) | 2010-11-05 | 2019-12-03 | The Board Of Trustees Of The Leland Stanford Junior University | Control and characterization of memory function |
| US8696722B2 (en) | 2010-11-22 | 2014-04-15 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic magnetic resonance imaging |
| US20120244174A1 (en) * | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| CN105755044A (zh) | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| US9155489B2 (en) | 2011-07-05 | 2015-10-13 | Deborah Zelinsky | Devices for modulation of retinal stimulation and/or retinal signal processing and methods of use thereof |
| EP2736406B1 (en) | 2011-07-25 | 2019-09-04 | NeuroNexus Technologies, Inc. | Neuromodulation transfection system with means for active fluid delivery |
| US10493297B2 (en) | 2011-07-25 | 2019-12-03 | Neuronexus Technologies, Inc. | Neuromodulation transfection system with passive fluid delivery |
| US9782091B2 (en) | 2011-07-25 | 2017-10-10 | Neuronexus Technologies, Inc. | Opto-electrical device for artifact reduction |
| HK1199768A1 (en) | 2011-08-25 | 2015-07-17 | 康奈尔大学 | Retinal encoder for machine vision |
| US9192650B2 (en) | 2011-08-30 | 2015-11-24 | The Regents Of The University Of Michigan | Methods of inhibiting photoreceptor apoptosis by eliciting the Faim2 antiapoptotic pathway |
| EP2776459A1 (en) * | 2011-11-08 | 2014-09-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Rod cell-specific promoter |
| WO2013071231A1 (en) * | 2011-11-12 | 2013-05-16 | Massachusetts Institute Of Technology | Channelrhodopsins for optical control of cells |
| ES2724803T3 (es) | 2011-12-16 | 2019-09-16 | Univ Leland Stanford Junior | Polipéptidos opsinas y métodos de utilización de los mismos |
| US8858929B2 (en) | 2012-01-04 | 2014-10-14 | Technion Research & Development Foundation Limited | Optically sensitive cell network |
| CN104363961B (zh) | 2012-02-21 | 2017-10-03 | 斯坦福大学托管董事会 | 用于治疗盆底神经源性病症的组合物和方法 |
| CA2866405A1 (en) | 2012-03-05 | 2013-09-12 | Wayne State University | Identification of channelopsin-2 (chop2) mutations and methods of use |
| WO2014033095A1 (en) | 2012-08-27 | 2014-03-06 | Friedrich Miescher Institute For Biomedical Research | Retinal off circuit-specific promoter |
| US9636380B2 (en) | 2013-03-15 | 2017-05-02 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of inputs to the ventral tegmental area |
| JP6594854B2 (ja) | 2013-03-15 | 2019-10-23 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 行動状態の光遺伝学的制御方法 |
| JP6549559B2 (ja) | 2013-04-29 | 2019-07-24 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 標的細胞における活動電位の光遺伝学的調節のための装置、システム及び方法 |
| EP3003391B1 (en) | 2013-05-31 | 2021-09-22 | The Regents of The University of California | Adeno-associated virus variants and methods of use thereof |
| JP6621747B2 (ja) | 2013-08-14 | 2019-12-18 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 疼痛を制御するための組成物及び方法 |
| JP6118239B2 (ja) | 2013-11-29 | 2017-04-19 | 雅敏 堀 | 害虫の防除方法及び防除装置 |
| US20170007720A1 (en) * | 2014-02-21 | 2017-01-12 | University Of Florida Research Foundation, Inc. | Methods and compositions for gene delivery to on bipolar cells |
| GB201403260D0 (en) | 2014-02-25 | 2014-04-09 | Univ Manchester | Treatment of retinal degeneration using gene therapy |
| EP4678754A3 (en) * | 2014-03-11 | 2026-04-08 | Wayne State University | A modified mglur6 promoter and methods of use |
| EP3800191B1 (en) | 2014-03-17 | 2025-08-20 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
| WO2015142984A1 (en) | 2014-03-18 | 2015-09-24 | Washington University | Methods and compositions for red-shifted chromophore substitution for optogenetic applications |
| WO2015195769A2 (en) | 2014-06-18 | 2015-12-23 | President And Fellows Of Harvard College | Optogenetic probes for measuring membrane potential |
| WO2016115333A1 (en) | 2015-01-15 | 2016-07-21 | President And Fellows Of Harvard College | Optical selection of cells |
| GB201503008D0 (en) * | 2015-02-23 | 2015-04-08 | Ucl Business Plc | Treatment |
| US11021519B2 (en) | 2015-03-02 | 2021-06-01 | Adverum Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| US10519205B2 (en) | 2015-03-19 | 2019-12-31 | The Board Of Regents Of The University Of Texas System | Compositions and methods for use of anion channel rhodopsins |
| JP6836999B2 (ja) | 2015-03-24 | 2021-03-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | アデノ随伴ウイルス変異体及びその使用方法 |
| KR102489987B1 (ko) | 2015-04-20 | 2023-01-17 | 코넬 유니버시티 | 차원 데이터 축소를 이용하는 머신 비전 |
| WO2016209654A1 (en) | 2015-06-22 | 2016-12-29 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and devices for imaging and/or optogenetic control of light-responsive neurons |
| WO2017093566A1 (en) * | 2015-12-04 | 2017-06-08 | Universite Pierre Et Marie Curie (Paris 6) | Promoters and uses thereof |
| EP3426287A4 (en) | 2016-03-09 | 2020-03-11 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Methods and kits for use in preventing and treating vulvovaginal candidiasis |
| AU2017257169B2 (en) | 2016-04-29 | 2021-07-08 | Adverum Biotechnologies, Inc. | Evasion of neutralizing antibodies by a recombinant adeno-associated virus |
| WO2017187272A1 (en) * | 2016-04-29 | 2017-11-02 | Gensight Biologics Sa | Optogenetic visual restoration using chrimson |
| US20170319669A1 (en) * | 2016-05-03 | 2017-11-09 | Wayne State University | Method of enhancing viral-mediated gene delivery |
| US20190209708A1 (en) * | 2016-05-17 | 2019-07-11 | Friedrich Miescher Institute For Biomedical Research | Novel therapeutic tools and methods for treating blindness |
| US11400311B2 (en) | 2016-06-17 | 2022-08-02 | Gensight Biologics | Device for illuminating an object with a controlled light intensity and associated method |
| AU2017302013B2 (en) | 2016-07-29 | 2022-05-26 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| EP3504227A1 (en) | 2016-08-29 | 2019-07-03 | Wayne State University | Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof |
| CA3040179A1 (en) | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
| RU2766353C2 (ru) * | 2016-11-02 | 2022-03-15 | Фридрих Мишер Инститьют Фор Байомедикал Рисерч | Synp198, промотор для специфической экспрессии генов в ганглионарных клетках сетчатки, избирательных в отношении направления |
| JP6181278B1 (ja) | 2016-12-22 | 2017-08-16 | Ｊｉｇ−Ｓａｗ株式会社 | 可視光波長変換部を有する頭部装着型映像提示装置 |
| WO2018134168A1 (en) | 2017-01-17 | 2018-07-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of expressing a polynucleotide of interest in the cone photoreceptors |
| US11294165B2 (en) | 2017-03-30 | 2022-04-05 | The Board Of Trustees Of The Leland Stanford Junior University | Modular, electro-optical device for increasing the imaging field of view using time-sequential capture |
| US20200115419A1 (en) * | 2017-04-12 | 2020-04-16 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | New optogenetic tool |
| CA3053154A1 (en) | 2017-06-30 | 2019-01-03 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsids and methods of use thereof |
| JP2020534788A (ja) | 2017-08-28 | 2020-12-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アデノ随伴ウイルスカプシド変異体及びその使用方法 |
| CN111867635A (zh) | 2017-10-20 | 2020-10-30 | 法国国家卫生及研究医学协会 | 包括视网膜下递送治疗有效量的重组aav9衍生载体的在对象的视锥细胞光感受器中表达目的多核苷酸的方法 |
| SG11202005024QA (en) | 2017-11-30 | 2020-06-29 | Friedrich Miescher Institute For Biomedical Res | Synpiii, a promoter for the specific expression of genes in retinal pigment epithelium |
| US20190275169A1 (en) * | 2018-03-07 | 2019-09-12 | Circuit Therapeutics, Inc. | Targeted immunosuppression for optogenetic intervention |
| JP7371083B2 (ja) * | 2018-07-20 | 2023-10-30 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 遺伝子治療発現ベクターの眼内送達 |
| JPWO2020054868A1 (ja) * | 2018-09-14 | 2021-08-30 | 国立大学法人 名古屋工業大学 | 光応答性タンパク質及びその利用 |
| WO2020201828A1 (en) | 2019-04-05 | 2020-10-08 | Tauc3 Biologics Limited | Anti-tauc3 antibodies and uses thereof |
| TW202532428A (zh) | 2019-04-26 | 2025-08-16 | 美商愛德維仁生物科技公司 | 用於玻璃體內遞送之變異體aav蛋白殼 |
| EP3733139A1 (en) | 2019-05-02 | 2020-11-04 | Gensight Biologics | Viewing apparatus and method for projecting a light signal |
| CN110521842A (zh) * | 2019-05-06 | 2019-12-03 | 高思 | 人眼晶状体和视网膜感光细胞营养素裹养眼明目草药糖果 |
| AU2020385387A1 (en) * | 2019-11-22 | 2022-06-02 | Fondazione Irccs Ca' Granda Ospedale Maggiore Foliclinico | Materials and methods for treatment of disorders associated with the IGHMBP2 gene |
| GB202002073D0 (en) * | 2020-02-14 | 2020-04-01 | Ucl Business Ltd | Horizontal cells |
| WO2021165876A1 (en) * | 2020-02-19 | 2021-08-26 | Friedrich Miescher Institute For Biomedical Research | Novel therapeutical tools and methods using temperature-senstive receptors for treating blindness |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| CA3179895A1 (en) | 2020-04-24 | 2021-10-28 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for preventing induction of immune responses to the transduced cells expressing a transgene product after ocular gene therapy |
| AU2022299552A1 (en) * | 2021-06-25 | 2024-01-04 | Oxford Biomedica (Us) Llc | Adeno-associated virus packaging systems |
| KR20260015799A (ko) | 2023-05-04 | 2026-02-03 | 젠사이트 바이올로직스 | 관찰 장치 |
| EP4704972A1 (en) | 2023-05-04 | 2026-03-11 | Gensight Biologics | Method for controlling the illumination of a surface of an object by a projecting unit and associated method and devices |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4498919A (en) * | 1983-10-31 | 1985-02-12 | Corning Glass Works | Method for making colored photochromic prescription ophthalmic lenses |
| US6610287B1 (en) * | 1990-04-16 | 2003-08-26 | The General Hospital Corporation | Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
| US5827702A (en) | 1994-10-31 | 1998-10-27 | Genentech, Inc. | Ocular gene therapy |
| IT237434Y1 (it) | 1997-04-17 | 2000-09-13 | Philco Italiana | Lavatrice con carrello per il suo spostamento |
| EP0977880A2 (en) | 1997-04-21 | 2000-02-09 | University Of Florida | Materials and methods for treatment of retinal diseases |
| CA2346262A1 (en) | 1998-09-17 | 2000-03-23 | University Of Florida | Methods for treatment of degenerative retinal diseases |
| US7056502B2 (en) | 2000-04-28 | 2006-06-06 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids |
| WO2002082904A2 (en) | 2001-04-13 | 2002-10-24 | The Trustees Of The University Of Pennsylvania | Method of treating or retarding the development of blindness |
| AU2002323210A1 (en) * | 2001-08-16 | 2003-03-03 | Sloan Kettering Institute For Cancer Research | Bio-synthetic photostimulators and methods of use |
| DE10216005A1 (de) * | 2002-04-11 | 2003-10-30 | Max Planck Gesellschaft | Verwendung von biologischen Photorezeptoren als direkt lichtgesteuerte Ionenkanäle |
| AU2003274397A1 (en) | 2002-06-05 | 2003-12-22 | University Of Florida | Production of pseudotyped recombinant aav virions |
| WO2004009022A2 (en) * | 2002-07-18 | 2004-01-29 | The General Hospital Corp. | Method for augmenting vision in persons suffering from photoreceptor cell degeneration |
| US7321796B2 (en) | 2003-05-01 | 2008-01-22 | California Institute Of Technology | Method and system for training a visual prosthesis |
| US7186699B2 (en) * | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| US7427138B2 (en) * | 2003-11-05 | 2008-09-23 | Neurovision, Inc. | Method and apparatus for improving visual perception |
| WO2005123183A2 (en) | 2004-06-11 | 2005-12-29 | University Of South Florida | Electroporation device and method for delivery to ocular tissue |
| EP1919497B1 (en) * | 2005-07-22 | 2020-02-12 | The Board of Trustees of the Leland Stanford Junior University | Light-activated cation channel and uses thereof |
| CN101484005A (zh) * | 2006-05-04 | 2009-07-15 | 韦恩州立大学 | 通过向体内递送视紫红质核酸恢复视觉响应 |
| WO2011140279A1 (en) | 2010-05-04 | 2011-11-10 | Wayne State University | Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells |
| KR101945962B1 (ko) | 2010-09-08 | 2019-02-08 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | 돌연변이 채널로돕신 2 |
| CA2866405A1 (en) | 2012-03-05 | 2013-09-12 | Wayne State University | Identification of channelopsin-2 (chop2) mutations and methods of use |
-
2007
- 2007-05-04 CN CNA2007800252180A patent/CN101484005A/zh active Pending
- 2007-05-04 AU AU2007247929A patent/AU2007247929A1/en not_active Abandoned
- 2007-05-04 CA CA002685900A patent/CA2685900A1/en not_active Abandoned
- 2007-05-04 WO PCT/US2007/068263 patent/WO2007131180A2/en not_active Ceased
- 2007-05-04 EP EP07797340A patent/EP2019588A4/en not_active Ceased
- 2007-05-04 US US12/299,574 patent/US8470790B2/en active Active
- 2007-05-04 EP EP18176101.6A patent/EP3437473A1/en not_active Withdrawn
- 2007-05-04 JP JP2009510101A patent/JP2009536219A/ja active Pending
-
2013
- 2013-05-21 US US13/899,198 patent/US9730981B2/en active Active
- 2013-10-18 JP JP2013217117A patent/JP2014040469A/ja not_active Withdrawn
- 2013-11-13 AU AU2013257450A patent/AU2013257450B2/en not_active Ceased
-
2016
- 2016-04-01 JP JP2016074113A patent/JP2016121190A/ja not_active Withdrawn
-
2017
- 2017-08-14 US US15/676,573 patent/US20180214513A1/en not_active Abandoned
-
2018
- 2018-02-02 JP JP2018017334A patent/JP2018076377A/ja not_active Withdrawn
-
2019
- 2019-12-02 US US16/700,201 patent/US11883463B2/en active Active
-
2020
- 2020-09-07 JP JP2020149721A patent/JP2020203924A/ja active Pending
Non-Patent Citations (4)
| Title |
|---|
| JPN6012030893; Ａｎｄｉｎｇ Ｂｉ， ｅｔ ａｌ．: Ｎｅｕｒｏｎ Ｖｏｌ．５０, 200604, ｐｐ．２３-３３ * |
| JPN6013018092; Ｊ． Ｏｔｏｍｏ， ａｔ ａｌ．， Ｂｉｏｃｈｉｍｉｃａ ｅｔ Ｂｉｏｐｈｙｓｉｃａ Ａｃｔａ， １９９２， １１１２， ｐｐ７-１３ * |
| JPN6013018094; Ｊ． Ｏｔｏｍｏ， ａｔ ａｌ．， Ｂｉｏｃｈｉｍｉｃａ ｅｔ Ｂｉｏｐｈｙｓｉｃａ Ａｃｔａ， １９９５， １２４０， ｐｐ２４８-２５６ * |
| JPN6013018096; Ｊ．Ｋ．Ｌａｎｙｉ， ｅｔ ａｌ．， ＴＨＥ ＪＯＵＲＮＡＬ ＯＦ ＢＩＯＬＯＧＩＣＡＬ ＣＨＥＭＩＳＴＲＹ， １９９０， ２６５（３）， ｐｐ１２５３-１２６０ * |
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008201692A (ja) * | 2007-02-19 | 2008-09-04 | Tohoku Univ | 視覚機能の再生方法 |
| JP2013521017A (ja) * | 2010-02-26 | 2013-06-10 | コーネル ユニヴァーシティー | 人工網膜 |
| JP2016040000A (ja) * | 2010-02-26 | 2016-03-24 | コーネル ユニヴァーシティー | 人工網膜 |
| JP2013544494A (ja) * | 2010-09-08 | 2013-12-19 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | 変異チャネルロドプシン２ |
| JP2014524903A (ja) * | 2011-06-24 | 2014-09-25 | ハーク−シュトライト・メドテック・アクチェンゲゼルシャフト | 光感受性キメラｇｐｃｒタンパク質 |
| JP2019055980A (ja) * | 2013-03-14 | 2019-04-11 | ウェイン ステイト ユニバーシティー | 治療用化合物の眼への送達を増強する方法 |
| JP2016519063A (ja) * | 2013-03-14 | 2016-06-30 | ウェイン ステイト ユニバーシティー | 治療用化合物の眼への送達を増強する方法 |
| US11400167B2 (en) | 2016-02-23 | 2022-08-02 | Eyeserv Gmbh | Gene therapy for the treatment of a retinal degeneration disease |
| JP2019505239A (ja) * | 2016-02-23 | 2019-02-28 | アイサーブ ゲーエムベーハーＥｙｅｓｅｒｖ Ｇｍｂｈ | 網膜変性疾患を治療するための遺伝子治療 |
| JP7227765B2 (ja) | 2016-02-23 | 2023-02-22 | アイサーブ ゲーエムベーハー | 網膜変性疾患を治療するための遺伝子治療 |
| JP2024026791A (ja) * | 2016-09-02 | 2024-02-28 | 慶應義塾 | 視覚機能再生剤又は視覚機能低下予防剤 |
| US11932679B2 (en) | 2016-09-02 | 2024-03-19 | Keio University | Agent for restoring visual function or agent for preventing deterioration in visual function |
| WO2018043707A1 (ja) * | 2016-09-02 | 2018-03-08 | 学校法人慶應義塾 | 視覚機能再生剤又は視覚機能低下予防剤 |
| JP2022126804A (ja) * | 2016-09-02 | 2022-08-30 | 慶應義塾 | 視覚機能再生剤又は視覚機能低下予防剤 |
| JPWO2018043707A1 (ja) * | 2016-09-02 | 2019-07-25 | 学校法人慶應義塾 | 視覚機能再生剤又は視覚機能低下予防剤 |
| JP7427208B2 (ja) | 2016-09-02 | 2024-02-05 | 慶應義塾 | 視覚機能再生剤又は視覚機能低下予防剤 |
| JPWO2020148913A1 (ja) * | 2019-01-18 | 2021-12-02 | 株式会社レストアビジョン | 網膜疾患の予防および進行抑制、視覚認知行動機能の改善、および視覚機能強化 |
| WO2020148913A1 (ja) * | 2019-01-18 | 2020-07-23 | 俊英 栗原 | 網膜疾患の予防および進行抑制、視覚認知行動機能の改善、および視覚機能強化 |
| JP7299632B2 (ja) | 2019-01-18 | 2023-06-28 | 株式会社レストアビジョン | 網膜疾患の予防および進行抑制、視覚認知行動機能の改善、および視覚機能強化 |
| US11771741B2 (en) | 2019-09-13 | 2023-10-03 | Restore Vision Inc. | Nucleic acid construct that encodes chimeric rhodopsin |
| US12606606B2 (en) | 2019-09-13 | 2026-04-21 | Restore Vision Inc. | Nucleic acid construct that encodes chimeric rhodopsin |
| JPWO2021182646A1 (https=) * | 2020-03-13 | 2021-09-16 | ||
| WO2021182646A1 (ja) * | 2020-03-13 | 2021-09-16 | 国立大学法人名古屋工業大学 | 色認識のための光応答性タンパク質及びその利用 |
| JP7723983B2 (ja) | 2020-03-13 | 2025-08-15 | 国立大学法人 名古屋工業大学 | 色認識のための光応答性タンパク質及びその利用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007131180A2 (en) | 2007-11-15 |
| US20140121265A1 (en) | 2014-05-01 |
| EP2019588A2 (en) | 2009-02-04 |
| CN101484005A (zh) | 2009-07-15 |
| JP2016121190A (ja) | 2016-07-07 |
| AU2007247929A1 (en) | 2007-11-15 |
| US11883463B2 (en) | 2024-01-30 |
| AU2013257450B2 (en) | 2016-08-25 |
| US20210100875A1 (en) | 2021-04-08 |
| EP2019588A4 (en) | 2010-11-24 |
| CA2685900A1 (en) | 2007-11-15 |
| US9730981B2 (en) | 2017-08-15 |
| US20180214513A1 (en) | 2018-08-02 |
| JP2020203924A (ja) | 2020-12-24 |
| WO2007131180A3 (en) | 2008-07-31 |
| EP3437473A1 (en) | 2019-02-06 |
| JP2014040469A (ja) | 2014-03-06 |
| US20100015095A1 (en) | 2010-01-21 |
| JP2018076377A (ja) | 2018-05-17 |
| US8470790B2 (en) | 2013-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250213723A1 (en) | Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells | |
| JP2018076377A (ja) | ロドプシン拡散のインビボ送達による視覚応答の回復 | |
| US20240165198A1 (en) | Optogenetic visual restoration using chrimson | |
| JP2019528781A (ja) | 改善された光感受性を有するチャネルオプシン変異体における突然変異の特定及びその使用方法 | |
| JP2022110055A (ja) | プロテオソーム阻害剤を用いた眼におけるウイルス媒介遺伝子送達を向上させる方法 | |
| EP3261679B1 (en) | Gene therapy to improve vision | |
| HK40004342A (en) | Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids | |
| JP7792699B2 (ja) | 改変チャネルロドプシン | |
| HK1248595B (en) | Gene therapy to improve vision |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100430 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100430 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110415 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120614 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120906 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120913 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121113 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121120 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121213 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130418 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130717 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130724 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131210 |